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Epithelial ovarian cancer (EOC) was previously shown to be associated with
glycosylation changes of total serum and total IgG proteins. However, as a majority
of previous studies analyzed released glycan profiles, still little is known about IgG
subclass-specific alterations in ovarian cancer. Hence, in this study, we investigated
EOC-related glycosylation changes of the three most abundant IgG subclasses,
namely, IgG1, IgG2 and IgG3 isolated from sera of 87 EOC patients and 74 age-
matched healthy controls. In order to separate IgG2 and IgG3, we performed a
two-step affinity purification employing Protein A and Protein G Sepharose. After
tryptic digestion, IgG glycopeptides were enriched and measured by MALDI-TOF-
MS. Finally, EOC-related glycosylation changes were monitored at the level of
total agalactosylation, monogalactosylation, digalactosylation, sialylation, bisection and
fucosylation, which were calculated separately for each IgG subclass. Interestingly, aside
from an EOC-related increase in agalactosylation/decrease in monogalactosylation and
digalactosylation observed in all IgG subclasses, some subclass-specific trends were
detected. Glycosylation of IgG1 was found to be most strongly affected in EOC, as
it exhibited the highest number of significant differences between healthy controls
and EOC patients. Specifically, IgG1 was the only subclass that showed a significant
decrease in sialylation and a significant increase in fucosylation in EOC patients.
Interestingly, IgG2 and IgG3 that were often investigated collectively in previous studies,
were found to have distinct glycosylation patterns. IgG3 displayed stronger EOC-related
increase in agalactosylation/decrease in digalactosylation and was characterized by
notably higher sialylation, which consequently decreased in EOC patients. In conclusion,
our study indicates that IgG subclasses exhibit subtly distinct glycosylation patterns of
EOC-related alterations and that IgG1 and IgG3 agalactosylation show the strongest
association with CA125, the routine diagnostic marker. Additionally, our results show
that simultaneous analyses of IgG2 and IgG3 might lead to wrong conclusions as these
two subclasses exhibit noticeably different glycosylation phenotypes.
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INTRODUCTION
Glycosylation of proteins is one of the most common co-
translational and post-translational modifications that consists of
the covalent attachment of carbohydrate moieties to polypeptide
chains. Apart from increasing protein diversity, glycans are
known to play a broad range of roles; that is, they govern
the folding of nascent polypeptides in the ER, provide protein
physicochemical stability and modify their functions. Moreover,
they are involved in various biological processes including cell
signaling, extracellular interactions and immune responses (1,
2). Consequently, altered protein glycosylation was shown to
be associated with numerous inborn and acquired pathological
conditions (3, 4).
Among others, glycosylation changes were reported in ovarian
cancer (OC), which remains the most lethal gynecological
malignancy in women despite decades of research and better
understanding of its etiology (5). Its particularly high mortality
results from the lack of early diagnostic markers, which leads
to late primary diagnosis and 5-year survival rates as low as
29% in advanced-stage patients (6). In the absence of biomarkers
able to reliably detect OC at an early, still asymptomatic stage,
altered glycosylation of proteins attracted attention as a potential
source of complementary screening markers. Hence, in the last
decades, OC-related changes in glycosylation of total serum
and of individual proteins were broadly investigated by us (7–
9) and by other groups (10–13). Since carcinoma development
is accompanied by inflammation, we previously analyzed the
N-glycosylation profile of acute-phase proteins isolated from
serum samples of epithelial ovarian cancer (EOC) patients (14).
Obtained glycosylation profiles revealed not only significant
quantitative but also qualitative differences between healthy
controls and EOC patients. For instance, triantennary N-glycans
containing a (1–6) branch and a LewisX epitope or tetraantennary
N-glycans containing three LewisX epitopes were detected only in
EOC patients, which demonstrates their diagnostic potential (14).
In the present study, we aimed at further investigating
EOC-related glycosylation changes, turning our focus from
liver-originating acute-phase proteins to immunoglobulin G
(IgG), secreted by activated plasma B cells. Being present at a
concentration of 7–18 mg/ml, IgG represents the most abundant
glycoprotein in human serum (15). Each IgG molecule consists of
two heavy and two light chains that are covalently linked through
disulfide bridges to form a tetrameric Y-shaped structure.
Functionally, IgG can be divided into two distinctive parts:
fragment antigen binding (Fab), responsible for recognizing and
binding to specific antigens, and fragment crystallizable (Fc),
which exerts effector functions by interacting with complement,
Fc-gamma receptors (FcγRs) and neonatal Fc receptor (FcRn)
(16). Within the Fc part, each IgG heavy chain carries a single,
highly conserved glycosylation site at asparagine 297 that is
typically occupied by biantennary N-glycans of complex type (16,
17). A vast majority of Fc N-glycans is core-fucosylated and bears
0–2 galactose residues. Hence, the three most prominent IgG-Fc
glycoforms are G0F (no galactose and one core-fucose), G1F (one
galactose and one core-fucose) and G2F (two galactoses and one
core-fucose). A small proportion of IgG N-glycans can be further
extended by the addition of bisecting N-acetylglucosamine
(GlcNAc, N) and/or sialic acids (S) (17). Multiple studies showed
that IgG-Fc N-glycans are necessary for the maintenance of IgG
structural stability, quaternary conformation and induction of its
effector functions (18–20).
The presence of aberrantly glycosylated IgG antibodies
in the circulation of OC patients was described already in
2001 (21). Later, Saldova et al. (10) defined the nature of
these alterations, showing that the serum of OC patients
contains a higher fraction of IgG carrying agalactosylated
N-glycans and, conversely, lower proportions of those carrying
monogalactosylated, digalactosylated and sialylated glycan
structures. Their observations, based on the analysis of only
three OC serum samples, were further validated in bigger
cohort studies by Alley et al. (12) and Qian et al. (13), who
not only confirmed that OC was associated with a decreased
galactosylation and an increased agalactosylation of IgG but
also indicated that observed changes, when combined into a
ratio, were superior to routinely used CA125 for discrimination
between OC and benign gynecological conditions (13). Based
on their results, authors proposed that this ratio could act
as an adjunct diagnostic marker, which in combination with
CA125 could reduce the number of false-positive outcomes.
More recently, Ruhaak et al. examined glycosylation profiles of
three major immunoglobulins that are IgG, IgA and IgM, in
OC patients, showing that alterations of IgG glycosylation are
the most capable of discriminating between OC and healthy
individuals (22).
Interestingly, even though human IgG occurs as four
subclasses, namely, IgG1, IgG2, IgG3 and IgG4, a vast majority
of the above-mentioned studies monitored glycosylation
changes only at the level of total IgG, analyzing enzymatically
released IgG N-glycans. Even though Ruhaak et al. (22)
performed the analysis at the level of tryptic glycopeptides,
their study concentrated on finding the best-performing
OC classifier rather than revealing IgG subclass-specific
glycosylation alterations. Uncovering subclass-specific IgG
glycosylation profiles is, however, important since, despite
90% identity of their amino acid sequences, each subclass is
unique and varies with regard to antigen binding, triggering
effector functions, half-life and placental transport. Particular
attention should be given to IgG3, because its superior affinity
to activating FcγRs (i.e., FcγRI, FcγRIIa, FcγRIIIa, and
FcγRIIIb) and complement component 1q (C1q) makes it
the most potent pro-inflammatory IgG subclass (23). Despite
its unique character, analysis of IgG3 Fc-glycosylation is
rarely performed. This might not only be caused by its lower
concentration in blood but also by the fact that tryptic IgG3
glycopeptide containing asparagine 297 shares the same
peptide backbone as IgG2 or IgG4, depending on the IgG3
allotype (24).
Therefore, the aim of our study was to investigate the
subclass-specific distribution of IgG glycosylation changes in
patients suffering from primary EOC. By performing two-step
affinity purification, glycosylation profiles of the three most
abundant IgG subclasses, namely, IgG1, IgG2 and IgG3, could be
determined individually.
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MATERIALS AND METHODS
Sample Collection
Ethical approval was obtained from the Charité Institutional
Ethics Committee (EA4/073/06) and from the Ethics Committee
of the Medical Association of Hamburg (#OB/V/03). Written
informed consent was obtained from all study participants.
Eighty-seven primary EOC patients and 74 age- and sex-matched
healthy controls were enrolled in this study (Table 1). Blood
withdrawal was performed using clot activator serum tubes
(BD Vacutainer, NJ, USA). At first, blood was allowed to clot
for 30 min to 2 h at room temperature and then serum was
separated by centrifugation at 1,200 g for 15 min. The obtained
serum was aliquoted and stored at −80◦C until the time of
further analysis.
IgG Purification
IgG was isolated from 5 µl of human serum by sequential
two-step affinity purification using immobilized Protein A and
immobilized Protein G, as described elsewhere (24), with some
modifications. Briefly, 30 µl of Protein A Sepharose CL-4B slurry
(GE Healthcare, Eindhoven, The Netherlands) was transferred
to a 1.5-ml tube containing 400 µl of phosphate-buffered saline
(1× PBS). After the beads settled, the supernatant was discarded
and replaced with 400 µl of 1 × PBS, which was repeated
one more time. Following washing, the volume was brought
up to 400 µl with 1 × PBS and 5 µl of blood serum were
added. The sample mixture was incubated under agitation at
650 rpm for 1 h at room temperature. The entire mixture was
applied into a shortened 200-µl filter tip. The flow-through
was collected and Protein A Sepharose beads were washed with
5 × 200 µl of 1 × PBS and 3 × 200 µl of Milli-Q water.
Captured IgG1, IgG2 and IgG4 were eluted with 3 × 100 µl of
100 mM formic acid (Honeywell Fluka, Steinheim, Germany)
and evaporated to dryness in a vacuum centrifuge. Protein A
Sepharose beads were regenerated by washing with 2 × 100 µl
of 100 mM formic acid, 2 × 200 µl of Milli-Q water and
2 × 200 µl of 1 × PBS. The remaining supernatant was then
reapplied on the regenerated Protein A Sepharose column and
the flow-through was collected. Protein G Sepharose (30 µl
of slurry, GE Healthcare, Eindhoven, The Netherlands) was
conditioned as described above for Protein A Sepharose and
resuspended in the Protein A flow-through. The following
incubation, washing and elution steps were performed the same
way as described above for Protein A Sepharose. Collected eluates
were dried in vacuum centrifuge and stored at −20◦C until
further analysis.
TABLE 1 | Demographics of the cohorts used in this study.
Healthy EOC
No of patients 74 87
Age (mean ± SD) 59.8 ± 11.2 59.5 ± 10.3
CA125 (mean ± SD) 37.2 ± 106.8 929.4 ± 1,482.0
Age is shown in years and CA125 values are shown as kU/L.
SDS-PAGE and Western Blot
Protein A-bound IgG1, IgG2 and IgG4 fraction as well as Protein
G-bound IgG3 fraction were analyzed by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) followed by
Coomassie Brilliant Blue staining and western blot analysis using
a polyvinylidene fluoride (PVDF) membrane, all using standard
techniques. SDS-PAGE was performed using 10% acrylamide
gel under reducing conditions. The presence of IgG3 in Protein
A- and Protein G Sepharose-bound fractions was assessed by
western blot using recombinant anti-human IgG3 antibody
(1:1,000, Abcam, Cambridge, England).
Tryptic Digestion
Dried IgGs were dissolved in 50 µl of 50 mM ammonium
bicarbonate (Merck, Darmstadt, Germany) and shaken for 5 min.
Lyophilized sequencing-grade modified trypsin (20-µg vial;
Promega, Madison, WI) was dissolved in 100 µl of ice-cold
resuspension buffer provided by the manufacturer to obtain a
final concentration of 0.2 µg/µl. Five microliters of the solution,
corresponding to 1 µg of trypsin, were added to each IgG sample,
followed by overnight incubation at 37◦C. On the following day,
digested IgGs were dried out in a vacuum centrifuge and stored
at−20◦C until cotton HILIC purification.
Cotton HILIC Purification
IgG glycopeptides were enriched using self-made micro-spin
cotton HILIC columns as described elsewhere (25), with
minor modifications. Briefly, 10-µl filter tips (Greiner Bio-One,
Kremsmünster, Austria) were filled with fibers of cotton wool
pads and conditioned by washing with 3× 50 µl of Milli-Q water
and 3 × 50 µl of 80% ACN. Afterward, dried IgG samples were
resuspended in 50 µl of 80% ACN and loaded on the self-made
microcolumns. They were washed with 3 × 50 µl of 80% ACN
containing 0.1% TFA and then with 3 × 50 µl of 80% ACN. The
retained IgG glycopeptides were eluted with 6 × 50 µl Milli-Q
water, dried out in a vacuum centrifuge and stored at−20◦C until
MALDI-TOF-MS measurements.
MALDI-TOF-MS Measurements and Data
Processing
Dried IgG glycopeptide samples were dissolved in Milli-Q water,
and 1 µl was spotted on the stainless-steel MALDI target plate
(Bruker Daltonics, Bremen, Germany). Once dried, the sample
was overlaid with 1 µl of 2.5 mg/ml 4-chloro-α-cyanocinnamic
acid (ClCCA, Sigma-Aldrich, Germany) in 70% ACN and
allowed to air-dry at room temperature. All measurements
were performed on an Ultraflex III mass spectrometer (Bruker
Daltonics, Bremen, Germany) equipped with a Smart Beam
laser (laser frequency 100 Hz). Prior to measurement, the mass
spectrometer was calibrated with Peptide Calibration Standard
II (Bruker Daltonics, Bremen, Germany). Spectra were recorded
in reflectron negative ionization mode within the m/z window
from 1,000 to 5,000. For each mass spectrum, 5,000 laser
shots were accumulated using a partial “random-walk” laser
movement mode. Raw mass spectra were exported as ASCII text
files, and the subsequent processing that included recalibration,
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baseline subtraction and peak extraction was performed with the
MassyTools software (26). Recalibration was performed using the
list of six IgG1 glycopeptides (G0F, G1F, G0FN, G2F, G1FN and
G2FS1) for mass spectra of Protein A Sepharose-bound IgG or
the list of six IgG3 glycopeptides (G0F, G1F, G0FN, G2F, G1FN
and G2FS1) for mass spectra of Protein G Sepharose-bound
IgG. The absolute intensities of the detected glycopeptides were
normalized to the total area for IgG1, IgG2 and IgG3. Then,
by summing up relative intensities of respective glycopeptide
structures, six (or five in case of IgG2) derived glycosylation traits,
namely, agalactosylation, monogalactosylation, digalactosylation,
sialylation, bisecting GlcNAc and fucosylation, were calculated
separately for each IgG subclass, according to the formulas listed
below:
Agalactosylation (Agal) = G0F + G0FN + G0 + G0N + mono
G0F;
Monogalactosylation (Monogal) = G1F + G1FN + G1FS1 + G1
+ G1N + G1S1 + mono G1F;
Digalactosylation (Digal) = G2F + G2FN + G2FS1 + G2 +
G2N + G2S1;
Sialylation (Sial) = G1FS1 + G2FS1 + G1S1 + G2S1;
Bisecting GlcNAc (Bisec) = G0FN + G1FN + G2FN + G0N +
G1N + G2N;
Fucosylation (Fuc) = G0F + G1F + G2F + G0FN + G1FN +
G2FN + G1FS1 + G2FS1 + mono G0F + mono G1F.
Fucosylation of IgG2 was not evaluated in this study, as most
of its afucosylated glycopeptides could not be determined due
to the m/z overlap with fucosylated glycopeptides of IgG4.
Schematic representation of all detected structures can be
found in Table 2.
To determine inter-day reproducibility of an applied
workflow, the entire analytical procedure, including two-step
IgG purification, tryptic digestion, cotton HILIC enrichment,
and MALDI-TOF-MS measurement, was repeated using the
same serum sample on three consecutive days. Mean, SD and CV
values were calculated for six of the most abundant glycopeptide
structures of IgG1, IgG2 and IgG3. Results of reproducibility
testing are presented in Supplementary Figure S2.
Statistical Analysis
Statistical analyses were performed with SPSS version 25.0 (SPSS
Inc., Chicago, IL). Means and SD values of IgG1, IgG2 and IgG3
glycosylation traits in healthy controls and EOC patients were
calculated and are shown in Supplementary Table S1 and, in a
form of bar graphs, in Figure 2. In order to assess associations
between IgG glycosylation traits and EOC and to test whether
detected EOC-related differences were statistically significant, a
regression model was generated for each glycosylation trait. To
minimize the effect of age on IgG glycosylation (27, 28), all
regression models were corrected by including age as a covariate,
which resulted in the following formulas: “glycosylation trait
Y ∼ β1 ∗ patient’s status (0 = healthy control, 1 = EOC
patient) + β2 ∗ age + error”. Descriptive statistics of all regression
models, that is, regression beta coefficients (β), 95% confidence
intervals (95% CI) and p-values, are listed in Table 3. In the
following parts of this work, β1 and p1 values correspond to
EOC-related association, whereas β2 and p2 indicate age-related
association. After Bonferroni correction for glycosylation traits,
p-values smaller than or equal to 0.008 (for IgG1 and IgG3; 0.05/6
glycosylation traits) and 0.01 (for IgG2; 0.05/5 glycosylation
traits) were considered as statistically significant. Additionally,
for each IgG subclass, the relation between agalactosylation and
CA125 diagnostic marker (log-transformed values) was assessed
by fitting a linear regression model according to the formula
“IgG agalactosylation ∼ β ∗ CA125 + error”. Linear graphs with
coefficient of determination (R2), β coefficients and p-values are
presented in Figure 3. For each regression model, the distribution
of residuals was inspected and found to be normal.
RESULTS
In the present study, we analyzed the glycosylation profile of
the three most abundant IgG subclasses, namely, IgG1, IgG2
and IgG3, in serous EOC patients and age-matched healthy
controls by means of MALDI-TOF-MS. Glycosylation analysis
was performed at the level of tryptic glycopeptides in order
to obtain subclass-specific information. For this purpose, IgG
was isolated from serum using two-step affinity purification
employing, first, Protein A Sepharose that captures IgG1, IgG2
and IgG4, then Protein G Sepharose in order to bind the IgG3
contained in the Protein A Sepharose flow-through. Since the
amino acid sequence of IgG2 and IgG3 glycopeptides are quite
often identical (24, 29), the complete depletion of IgG2 in the
first purification step is essential for the subsequent analysis
of IgG3-specific glycosylation. As depicted in Supplementary
Figure S1A, residual IgG1, IgG2 and IgG4 were removed from the
flow-through fraction by its repeated loading on the regenerated
Protein A column. The applied procedure allowed the complete
binding of IgG1, IgG2 and IgG4, leaving only IgG3, which is
of higher mass, in the flow-through fraction (Supplementary
Figure S1B). In addition, the contamination of the Protein A
Sepharose-bound fraction with the IgG3 subclass was found to
be only minimal and hence negligible as judged by western blot
analysis (Supplementary Figure S1C).
Captured IgG fractions were digested with trypsin, which
generates the following peptide sequences: EEQYNSTYR in IgG1,
EEQFNSTFR in IgG2/IgG3 and EEQFNSTYR in IgG4, where
asparagine (N) is occupied by covalently linked N-glycans. Prior
to MALDI-TOF-MS measurements, obtained glycopeptides were
enriched using self-made cotton HILIC columns (25). Eventually,
measurements were performed in negative-ionization mode to
enable the simultaneous detection of neutral and underivatized
negatively charged (sialylated) IgG glycopeptides. The exemplary
MALDI-TOF mass spectra of Protein A- and Protein G-bound
fractions are presented in Figure 1, whereas all detected
structures included in the IgG glycopeptide analysis are listed in
Table 2. In total, we were able to detect 17 peaks corresponding to
IgG1 glycopeptides, 11 peaks of IgG2 glycopeptides and 16 peaks
of IgG3 glycopeptides. IgG4 glycopeptides were not investigated
due to very low signals and m/z overlap with some afucosylated
structures of the more abundant IgG2 glycopeptides (24). In case
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TABLE 2 | Tryptic glycopeptides of human IgG1, IgG2 and IgG3 detected in this study.
Structure composition m/z [M-H]− of detected glycoforms
IgG1 (EEQYNSTYR) IgG2 (EEQFNSTFR) IgG3 (EEQFNSTFR)
G0F 2,632.04 2,600.04 2,600.04
G1F 2,794.09 2,762.09 2,762.09
G2F 2,956.14 2,924.15 2,924.15
G0FN 2,835.12 2,803.12 2,803.12
G1FN 2,997.17 2,965.17 2,965.17
G2FN 3,159.22 3,127.23 3,127.23
G1FS1 3,085.18 3,053.19 3,053.19
G2FS1 3,247.24 3,215.24 3,215.24
Mono G0F 2,428.96 – –
Mono G1F 2,591.01 – –
G0 2,485.98 2,453.98 2,453.98
G1 2,648.03 –* 2,616.04
G2 2,810.08 –* 2,778.09
G0N 2,689.06 2,657.06 2,657.06
G1N 2,851.11 –* 2,819.12
G2N 3,013.16 –* 2,981.17
G1S1 – 2,907.13 2,907.13
G2S1 3,101.18 –* 3,069.18
Schematic representations are given in terms of a pink diamond (sialic acid), yellow circle (galactose), blue square (N-acetylglucosamine), green circle (mannose), red
triangle (fucose) and pep (peptide moiety). Structural composition is given in terms of G (galactose), F (fucose), N (bisecting GlcNAc), S (sialic acid), Mono (monoantennary).
*Isomeric glycopeptide species of IgG2 and IgG4.
of IgG1 and IgG3, glycopeptides carrying both core-fucosylated
and afucosylated N-glycans were analyzed. In turn, due to the
above-mentioned m/z overlap with fucosylated IgG4 structures
(24), a majority of IgG2 glycopeptides carrying afucosylated
N-glycans could not be determined and hence were not taken
into account during data analysis. Nevertheless, considering
that core-fucosylated structures were shown to constitute on
average 97% of all IgG2 glycoforms (30), exclusion of afucosylated
structures has only a minor impact on the entire analysis.
Almost all detected glycopeptides carried biantennary complex-
type N-glycans bearing zero to two galactoses. Minor amounts
of glycopeptides were additionally occupied by bisecting GlcNAc
and/or sialic acid.
Since IgG glycosylation is known to vary with age (27,
28), the significance of EOC-related changes was determined
with the help of regression models, considering age as a
covariate. As visible in Table 3, most of the investigated
glycosylation traits indeed showed a significant association with
age. Consistent with previous studies (31, 32), in all IgG
subclasses, agalactosylation was observed to positively correlate
with age, whereas monogalactosylation, digalactosylation and
sialylation showed a negative correlation, as judged by their
respective β coefficient values. Interestingly, glycosylation of
IgG1 was found to be the least affected by age, as only
three glycosylation traits (agalactosylation, digalactosylation and
sialylation) showed a significant association. On the contrary, in
the case of IgG3, a significant association with age was observed
for nearly all glycosylation traits, with fucosylation being the
only trait, whose p-value (p2 = 0.009) exceeded the Bonferroni-
corrected threshold of α = 0.008 (0.05/6 glycosylation traits),
deeming the association insignificant.
IgG1 Profiling
Among all three subclasses, the glycosylation profile of IgG1 was
found to be the most markedly altered in EOC patients. As visible
in Figure 2 and Table 3, IgG1 exhibited the most pronounced
increase in agalactosylation (β1 = 11.285, p1 = 1.3E−9) and
the most pronounced decrease in monogalactosylation and
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TABLE 3 | Associations between IgG glycosylation traits, EOC and age.
Glycosylation trait IgG1 IgG2 IgG3
β 95% CI p β 95% CI p β 95% CI p
Agal (1) EOC 11.285 7.831, 14.738 1.3E−9 6.056 2.737, 9.374 4.2E−4 9.120 5.242, 12.998 7.6E−6
(2) Age 0.418 0.256, 0.580 9.9E−7 0.524 0.369, 0.680 4.4E−10 0.609 0.428, 0.789 5.7E−10
Monogal (1) EOC −5.690 −7.630, −3.750 3.6E−8 −3.591 −5.666, −1.516 8.0E−4 −3.516 −5.369, −1.663 2.6E−4
(2) Age −0.118 −0.209, −0.027 0.011 −0.260 −0.357, −0.163 4.2E−7 −0.162 −0.249, −0.076 3.0E−4
Digal (1) EOC −5.596 −7.466, −3.726 2.0E−8 −2.465 −3.927, −1.003 1.1E−3 −5.604 −8.216, −2.992 4.0E−5
(2) Age −0.299 −0.387, −0.212 2.8E−10 −0.264 −0.333, −0.196 2.3E−12 −0.446 −0.568, −0.325 2.5E−11
Sial (1) EOC −0.576 −0.949, −0.202 0.003 −0.052 −0.644, 0.539 0.861 −2.360 −4.229, −0.492 0.014
(2) Age −0.039 −0.057, −0.022 1.9E−5 −0.072 −0.100, −0.044 8.3E−7 −0.275 −0.362, −0.188 4.6E−9
Bisec (1) EOC −0.852 −2.141, 0.437 0.193 −0.774 −1.764, 0.215 0.124 −0.564 −1.517, 0.388 0.244
(2) Age 0.052 −0.008, 0.112 0.091 0.038 −0.009, 0.084 0.110 0.084 0.040, 0.128 2.7E−4
Fuc (1) EOC 1.025 0.403, 1.648 0.001 – – – 0.459 −1.081, 1.998 0.557
(2) Age 0.005 −0.024, 0.034 0.721 – – – 0.096 0.024, 0.168 0.009
For all glycosylation traits, regression beta coefficients (β) are reported together with their 95% confidence interval (95% CI) and respective p-values (p). Bonferroni
corrected p-values smaller than or equal to 0.008 (for IgG1 and IgG3; 0.05/6 glycosylation traits) and 0.01 (for IgG2; 0.05/5 glycosylation traits) were considered as
statistically significant and are highlighted in bold. Representations of glycosylation traits are given in terms of Agal (agalactosylation), Monogal (monogalactosylation),
Digal (digalactosylation), Sial (sialylation), Bisec (bisecting GlcNAc) and Fuc (core-fucosylation).
FIGURE 1 | MALDI-TOF mass spectra of tryptic IgG-Fc glycopeptides of (A) Protein A Sepharose-bound fraction containing IgG1, IgG2 and IgG4 and (B) Protein G
Sepharose-bound fraction containing IgG3, both obtained from the same healthy individual. Black arrows indicate glycopeptides of IgG1, while red arrows indicate
IgG2 [in panel (A)] and IgG3 [in panel (B)]. IgG4 glycopeptides are not indicated as they were not analyzed in this study. Spectra were recorded in the
negative-ionization mode. Schematic representations are given in terms of a pink diamond (sialic acid), yellow circle (galactose), blue square (N-acetylglucosamine),
green circle (mannose), red triangle (fucose) and pep (peptide moiety).
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digalactosylation in EOC patients (β1 = −5.690, p1 = 3.6E−8
and β1 = −5.596, p1 = 2.0E−8, respectively). Interestingly,
even though IgG1 was found to be characterized by generally
low sialylation, it was the only subclass in which sialylation
was significantly decreased (p1 = 0.003) in EOC patients.
Additionally, IgG1 was also found to contain the highest
proportion of glycopeptides carrying bisecting GlcNAc
(Supplementary Table S1); however, no significant differences
were observed between healthy controls and EOC patients.
A vast majority (94–96%) of all detected IgG1 glycopeptides
carried core-fucosylated N-glycans. Remarkably, even though
the difference in IgG1 core-fucosylation between healthy controls
and EOC patients was minor (94.5 ± 2.2 in healthy controls
versus 95.5± 1.8 in EOC patients), the EOC-related increase was
found to be statistically significant (p1 = 0.001).
IgG2 Profiling
EOC-related glycosylation alterations of IgG2 partially resembled
those of IgG1; however, they were less pronounced (Figure 2
and Table 3). IgG2 agalactosylation was significantly increased
(β1 = 6.056, p1 = 4.2E−4), whereas monogalactosylation and
digalactosylation were significantly decreased in EOC patients
(β1 = −3.591, p1 = 8.0E−4 and β1 = −2.465, p1 = 1.1E−3,
respectively). Interestingly, IgG2 was found to be characterized
by particularly high agalactosylation, which was observed in both
investigated groups of individuals. For instance, while in IgG1
agalactosylation represented 31.6% and 42.7% in healthy controls
and EOC patients, respectively, in IgG2, these were 46.8% and
52.3%, respectively. Hence, on average, IgG2 agalactosylation
was about 12.4% higher in each investigated group. This was
further reflected by very low IgG2 digalactosylation, which
constituted only 11.9% in healthy controls and 9.5% in EOC
patients (Supplementary Table S1). IgG2 sialylation was slightly
higher than in IgG1; however, no significant differences were
detected between healthy controls and EOC patients. Likewise,
the abundance of bisecting GlcNAc in IgG2 was not found
to differ between both investigated groups. As mentioned in
previous sections, IgG2 fucosylation was not evaluated in this
study due to the m/z overlap with fucosylated IgG4 glycopeptides.
IgG3 Profiling
Analysis of IgG3 glycosylation is known to be hindered by its high
genetic polymorphism (24, 29). In the Caucasian population,
tryptic digestion of IgG3 usually results in the peptide sequence
EEQFNSTFR that is identical to that of IgG2 (29). However, due
to genetic polymorphism, in some individuals, tyrosine replaces
phenylalanine at position 296. In this study, 16 samples (i.e.,
seven healthy controls and nine EOC patients) were excluded
from the analysis of the IgG3 glycosylation due to the presence
of different peptide sequences and their resulting glycopeptide
moieties, leading to normalization issues. Nonetheless, this did
not lead to an age mismatch of investigated groups as the mean
age ± SD values remained at 61.6 ± 11.2 years in the healthy
group and 59.8± 10.3 years in the EOC group, with the difference
being statistically insignificant (data not shown). As visible in
Figure 2 and Table 3, EOC-related glycosylation changes in
IgG3 resembled those observed in other subclasses; however,
they were more pronounced than in IgG2 and less pronounced
than in IgG1. Agalactosylation of IgG3 increased in EOC patients
(β1 = 9.120, p1 = 7.6E−6), whereas monogalactosylation and
digalactosylation decreased (β1 = −3.516, p1 = 2.6E−4 and
β1 = −5.604, p1 = 4.0E−5, respectively). Interestingly, IgG3
was found to be characterized by markedly higher sialylation
than in IgG1 and IgG2. However, even though its decrease in
EOC patients was clearly visible, after Bonferroni correction,
the difference between both groups (p1 = 0.014) was deemed
statistically insignificant. Both bisecting GlcNAc and fucosylation
of IgG3 showed no significant differences between healthy
controls and EOC patients.
Association of IgG Agalactosylation With
CA125 Diagnostic Marker
Among all glycosylation traits, IgG agalactosylation displayed the
most profound EOC-related alteration. Thus, its association with
the most widely used biomarker for OC, namely, CA125, was
assessed in the entire cohort using linear regression models. As
visible in Figure 3, in each IgG subclass, agalactosylation showed
a significant positive association with CA125. As judged by R2
values, β coefficients and p-values, the strongest association was
observed in IgG1 (β = 2.793, p = 1.7E−8), whereas the weakest in
IgG2 (β = 1.267, p = 0.009). With an R2 of 0.074, a β coefficient of
1.856 and a p-value of 9.6E−4, IgG3 displayed a slightly stronger
association between its agalactosylation and CA125 than that
observed in IgG2 but weaker than that in IgG1.
DISCUSSION
In the present study, we investigated the EOC-related
glycosylation changes in the three most abundant IgG subclasses,
namely, IgG1, IgG2 and IgG3. IgG glycosylation in OC was
already examined by several research groups including ours
(9, 10, 12, 13, 22), demonstrating quantitative changes in
galactosylation/agalactosylation and its utility to improve the
detection of OC. Nevertheless, previous studies monitored the
glycosylation profile of total IgG at the level of enzymatically
released N-glycans. Owing to the fact that about 15–20%
of IgG molecules might contain additional N-glycosylation
sites within variable domains of Fab fragments, this approach
generates information that is neither Fc-/Fab-specific nor
subclass-specific. In the present study, analysis of EOC-related
changes in IgG glycosylation was performed at the level of
tryptic glycopeptides, incorporating an affinity separation of
IgG3 to ensure the subclass specificity of obtained glycosylation
profiles and to allow a separate examination of three of the most
abundant IgG subclasses.
In accordance with previous OC reports (10, 12, 13,
22), EOC was found to be associated with increased IgG
agalactosylation/decreased IgG galactosylation (in this study
categorized as monogalactosylation and digalactosylation) in
all investigated subclasses. Significantly, these alterations were
shown to have relevant biological consequences. Agalactosylated
IgG glycoforms are known to act in a pro-inflammatory manner,
as they are able to activate the complement system via an
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FIGURE 2 | Comparison of (A) IgG1-, (B) IgG2- and (C) IgG3-specific glycosylation profiles between healthy controls and EOC patients. Relative abundance of given
glycosylation traits was obtained by summing up relative intensities of the corresponding tryptic glycopeptides detected by MALDI-TOF-MS. Bars represent mean
relative abundance and error bars represent standard deviation. p-values were obtained from regression analysis, adjusting for age and patients’ status (0 = healthy
control, 1 = EOC). After Bonferroni correction for glycosylation traits, statistically significant differences are indicated as ∗p ≤ 0.008, ∗∗p ≤ 0.001 and ∗∗∗p ≤ 0.0001
in case of IgG1 and IgG3, and ∗p ≤ 0.01, ∗∗p ≤ 0.002 and ∗∗∗p ≤ 0.0002 in case of IgG2.
FIGURE 3 | Association between IgG subclass-specific agalactosylation (Y-axis) and log (CA125), the routine diagnostic marker (X-axis). Descriptive statistics are
shown for the total cohort and are given in terms of R2 (coefficient of determination), β (regression β coefficient) and p (p-values). IgG1 is shown on the left, IgG2 in
the middle and IgG3 on the right.
alternative pathway (33, 34) and the lectin pathway, after
binding to mannose-binding lectin (19, 35). Although molecular
regulations of the above-described changes are not yet fully
understood, in rheumatoid arthritis, a similar trend of reduced
IgG galactosylation was shown to result from decreased activity
of galactosyltransferase in IgG-producing plasma B cells (36).
Aside from an EOC-related increase in
agalactosylation/decrease in galactosylation observed
consistently in all investigated IgG subclasses, we detected
some distinct subclass-specific trends. Specifically, glycosylation
of IgG1 was found to be the most strongly affected in EOC,
and its agalactosylation showed the strongest association with
the CA125 diagnostic marker. Our observations are therefore
in line with the results of Ruhaak et al. (22), who showed that
glycopeptides of this most abundant IgG subclass exhibit the
highest diagnostic potential in EOC. Furthermore, our study
revealed that IgG1 undergoes the greatest EOC-related reduction
in monogalactosylated and digalactosylated glycopeptides,
which might indicate its strongest transformation toward
a pro-inflammatory phenotype during EOC development.
Interestingly, Saito et al. (37) showed that in gastric cancer
patients, a decreased IgG1 concentration was significantly
correlated with a poor prognosis. As the serum concentration
of other IgG subclasses showed no relation to patient outcome,
authors concluded that IgG1 must play the most important
role in tumor immunity. Remarkably, in our study, IgG1 was
also found to be the only subclass whose fucosylation was
significantly increased in EOC patients. Our observations are
in agreement with the results of Plomp et al. (30), showing that
increased IgG fucosylation is characteristic for individuals with
high inflammation, which occurs frequently in OC patients (38).
Since IgG core-fucosylation is known to considerably reduce
binding to FcγRIIIa and FcγRIIIb receptors, its increase might
lead to reduced ADCC activity. As much as this effect may be
detrimental to patients, it could be advantageous to cancer by
promoting its progression.
Interestingly, the glycosylation profile of IgG2, marked by
particularly low galactosylation, was found to be distinctly
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different from that of IgG1 and IgG3. This observation implies
that a common approach of simultaneous analysis of IgG2 and
IgG3 might lead to misleading results. IgG2 was previously
reported to exhibit the lowest affinity for FcγRs and the lowest
ADCC activity among all IgG subclasses (23, 39). Also, as
reported by Plomp et al. (30), IgG2 glycosylation showed
weaker association with markers of inflammation and metabolic
health than IgG1 and IgG4, indicating its rather limited role
in inflammation. Additionally, decreased IgG2 concentrations
were reported in various cancer types, including ovarian, gastric
and liver cancer (22, 40, 41), which might indicate that IgG2
plays a secondary role in cancer development. In line with all
those reports, in our study, IgG2 glycosylation traits showed the
weakest association with EOC and the CA125 diagnostic marker.
An essential part of our study was devoted to the investigation
of IgG3-specific glycosylation changes in EOC patients, as to the
best of our knowledge, it has not been studied so far. Despite
being relatively underrepresented (approximately 5–8% of total
IgG), IgG3 deserves special attention, as in many ways, it is a
unique IgG subclass. Its separation can be accomplished due to a
particular feature of its amino acid sequence, that is, the presence
of arginine instead of histidine at position 435 that prevents
its binding to Protein A (42). Moreover, due to its superior
affinity toward activating FcγRs and C1q, IgG3 was shown
to be the strongest inducer of Fc-mediated effector functions,
including ADCC and CDC (23). Despite its discrete character,
glycosylation of IgG3 is rarely determined individually. Instead,
it is investigated in combination with IgG2, which, as shown in
our study, has a markedly different glycosylation profile. Indeed,
in terms of glycosylation and EOC-related glycosylation changes,
IgG3 was found to more closely resemble IgG1 than IgG2.
Interestingly, even though an observed EOC-related decrease
in IgG3 sialylation was statistically insignificant after multiple
testing corrections, we could confirm the overall high IgG3
sialylation when compared to IgG1 and IgG2, already reported
in the literature (41, 43). Although the molecular regulation of
increased IgG3 sialylation is not completely understood, it could
possibly be related to higher accessibility of IgG3 Fc-attached
N-glycans for sialyltransferases due to structural differences
within its Fc-part (42). Additionally, it was proposed that
elevated IgG3 sialylation could result from different processing
by B-cell-independent sialidases and sialyltransferases present in
serum (43, 44). Having in mind that addition of sialic acid acts as
a functional switch turning IgG molecule from pro-inflammatory
state to an anti-inflammatory state, in physiological conditions
(healthy controls), high IgG3 sialylation could play a protective
role by limiting its excessive inflammatory responses. In turn,
a decrease of IgG3 sialylation in EOC patients might indicate
a disease-related transformation toward a pro-inflammatory
phenotype, a phenomenon that was observed for other cancer
types (40, 45).
IgG glycosylation has already been investigated in various
cancer types, often revealing associations with patient survival
rate, response to therapy and diagnostic markers. For instance,
in gastric cancer patients, a high level of digalactosylated IgG2
glycoforms was shown to be an indicator of better survival (40),
whereas an IgG glycosylation-based model proposed by Qin et al.
(46) could accurately predict response to neoadjuvant therapy. In
turn, in prostate cancer, the ratio of IgG agalactosylated structures
to the sum of monogalactosylated and digalactosylated ones
strongly correlated with levels of prostate-specific antigen (PSA),
which is the most prevalently used prostate cancer biomarker
(47). In our study, IgG agalactosylation showed a strong positive
association with CA125, the serum routine biomarker. While
comparisons between IgG glycosylation and CA125 have already
been reported (13, 22), this is the first study showing associations
with CA125 in a subclass-specific manner. Interestingly, as
agalactosylation of all subclasses was found to significantly
associate with the CA125 marker, the strongest relation was
observed for IgG1 and IgG3.
In line with previous reports (27, 28, 48), glycosylation
profiles of all three IgG subclasses were observed to alter with
increasing age. Interestingly, when compared to other subclasses,
glycosylation of IgG1, which displayed the most dramatic EOC-
related alterations and the strongest association with CA125, was
observed to be the least affected by age. This could indicate
that age-related glycosylation changes might diminish differences
between older healthy controls and EOC patients, thereby
hindering disease discrimination.
In conclusion, by analyzing EOC-related glycosylation
changes in the three most abundant IgG subclasses separately,
our study broadens the current understanding of molecular
backgrounds of EOC pathogenesis. Interestingly, while
glycosylation alterations of all IgG subclasses were observed
to follow similar patterns, EOC-related changes were most
pronounced in IgG1, which might indicate its particularly
important role in OC. As subtle subclass-specific characteristics
were also detected, our study highlights the importance of
independent analysis of IgG subclasses, particularly in respect to
IgG2 and IgG3 subclasses.
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FIGURE S1 | (A) Schematic representation of two-step IgG affinity isolation from
serum using Protein A and Protein G Sepharose. (B) Coomassie stained
SDS-PAGE gel presenting Protein A Sepharose-bound fraction containing IgG1,
IgG2 and IgG4, and Protein G Sepharose-bound fraction containing IgG3. The
band of IgG3 heavy chain appears higher in the gel due to its higher molecular
mass. (C) Western blot analysis of (1) Protein A and (2) Protein G
Sepharose-bound fractions using anti-human IgG3 antibody, showing negligible
IgG3 contamination of Protein A-bound fraction.
FIGURE S2 | Inter-day reproducibility of the IgG subclass-specific glycosylation
analysis. The entire analytical procedure including two-step IgG purification, tryptic
digestion, cotton-HILIC enrichment and MALDI-TOF-MS measurement were
repeated using the same serum sample on three consecutive days. Relative
intensities are shown for the six most abundant glycopeptide structures of IgG1,
IgG2 and IgG3. Average is shown as mean ± SD. Mean CV of six presented
glycopeptides were 1.87 (IgG1), 2.97 (IgG2) and 3.11 (IgG3), indicating good
reproducibility of the method.
TABLE S1 | Mean relative intensities and SD values of IgG glycosylation traits in
healthy controls and EOC patients. Representations of glycosylation traits are
given in terms of Agal (agalactosylation), Monogal (monogalactosylation), Digal
(digalactosylation), Sial (sialylation), Bisec (bisecting GlcNAc), Fuc
(core-fucosylation).
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